FDA peptide compounding policy is pending White House review
OIRA lists a pending FDA notice, "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94, HHS/FDA, stage Notice). Received 14 October 2026, no legal deadline, not economically significant. It is pending EO 12866 review. As of 17 October 2026 the policy has not been issued, and its text and covered peptides are not public.
Reuters reported on 15 October 2026 that the filing gives no details of the policy. The report said the Associated Press, citing two people familiar with the matter, described compounding of some popular peptides, including BPC-157, and that those peptides are not FDA-approved as safe or effective. Reuters also reported that Hims & Hers had said it plans to offer peptides if regulations permit.
Holland & Knight wrote on 16 October 2026 that no peptide has been added to the 503A Bulks List. It said the Pharmacy Compounding Advisory Committee voted on 23-24 July 2026 to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, and against Emideltide (DSIP). BPC-157, KPV, and TB-500 each passed 8-6 with one abstention. The votes are advisory. FDA staff briefing documents dated 29 June 2026 had recommended against all seven. The firm's analysis, not an FDA decision, is enforcement discretion for state-licensed 503A pharmacies: no product approval, no research-use-only, supplement, or 503B coverage, and withdrawal without rulemaking. The firm expects a lasting federal pathway in 2027-2028.
What this means for prices we track
None of those six peptides is a treatment this catalog prices. These are calendar-month continuing prices from the catalog on 22 October 2026. The Price Index uses the same rule.
Sermorelin injection: 7 providers, low $99, median $199, high $199, checked 20 October 2026 to 22 October 2026.
Oral sermorelin: 3 providers, low $99, median $129, high $179, checked 20 October 2026 to 22 October 2026.
NAD+ injection: 11 providers, low $93, median $159, high $249, checked 20 October 2026 to 22 October 2026.
NAD+ nasal spray: 5 providers, low $93, median $159, high $249, checked 20 October 2026 to 22 October 2026.
Oral NAD+: 1 providers, low $199, median $199, high $199, checked 22 October 2026.
Glutathione injection: 4 providers, low $99, median $149, high $159, checked 20 October 2026 to 22 October 2026.
The policy text is not public, so we cannot say whether it affects any of these rows. A recorded price or availability change will be added to the price-change log.